SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AutoImmune-AIMM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don Lachot who wrote (128)6/5/1997 9:28:00 AM
From: Dr. John M. de Castro   of 298
 
The results were not very impressive. That is why the market didn't react. As reported oral tolerance did not produce a significant effect on the primary end point of the study which was time to occular inflamation attack. There was a trend (p=.08) such that patients with S antigen could be weaned easier off of immunosuppressants than placebo. This is another case of results that aren't really positive but have enough trends to entice further study. This is not what AIMM needs.

John de C
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News